GlassScriptPhysician profile
Beth Ann Good
NPI 1568594497
$28,746.52
in general payments reported to CMS, 2019-2025
19 companies · $77.75 in 2025
The $77.75 reported for 2025 was less than what a typical Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,133 · 2022: $5,027 · 2023: $14K · 2024: $5,020 · 2025: $77.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $3,176 · Food and Beverage: $2,356 · Education: $29.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,025.00 |
| Travel and Lodging | $3,175.53 |
| Food and Beverage | $2,355.69 |
| Education | $29.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25,908.99 | 2021-2024 | |
| Neuronetics, INC. | $2,204.66 | 2023-2025 | Neurostar Tms Therapy System |
| Tempus Ai, INC | $107.56 | 2024 | |
| Neurocrine Biosciences, INC. | $83.16 | 2021-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $75.85 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $54.11 | 2023-2024 | Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $49.51 | 2024 | Cobenfy |
| Alkermes, INC. | $45.40 | 2022-2023 | Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $39.55 | 2021 | |
| Sunovion Pharmaceuticals INC. | $35.45 | 2021 | |
| Lundbeck LLC | $27.14 | 2023 | Brintellix |
| Indivior INC. | $22.27 | 2024 | Sublocade |
| Axsome Therapeutics, INC. | $18.28 | 2023 | Auvelity |
| Owp Pharmaceuticals, INC. | $14.23 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.13 | 2024 | Fanapt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.99 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.68 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $13.66 | 2022 | |
| Corium, LLC | $4.90 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.